KEY INVESTOR INFORMATION

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

VanEck Genomics and Healthcare Innovators UCITS ETF (the "Fund") a sub-fund of VanEck UCITS ETFs plc (the "Company") Share Class: USD A ISIN: IE000B9PQW54 This Fund is managed by VanEck Asset Management B.V., a subsidiary of Van Eck Associates Corporation.

Objectives and Investment Policy The Fund’s investment objective is to replicate, before fees and expenses, the

swaps and swaps on the Index), currency forwards and non-deliverable forwards MVIS Global Future Healthcare ESG Index (the “Index”).

(a forward contract that does not require settlement on maturity) (NDFs). The In order to seek to achieve its investment objective, the Manager will normally

Fund may also invest in ancillary liquid assets and money market instruments use a replication strategy by investing directly in the underlying equity securities which may include bank deposits, depositary receipts, certificates of deposit, of the MVIS Global Future Healthcare ESG Index (the “Index”) being the stock,fixed or floating rate instruments (treasury bills), commercial paper, floating rate American depository receipts (ADRs), and global depository receipts (GDRs).

notes and freely transferable promissory notes. The ancillary liquid assets, Such equity securities must be issued by companies who generate at least 50% money market instruments and FDI (other than permitted unlisted investments) (25% for current components) of their revenues from the following sub-themes:will be listed or traded on the Markets referred to in Appendix II of the (A) Healthcare therapies based on the targeting or modification of genetic

Prospectus. makeup of cells or uses mRNA (B) Technology platforms that enable theThe Fund may not invest more than 10% of its Net Asset Value in open-ended development of genetics-based healthcare therapies (C) Laboratory equipment or

collective investment. services used to test, code, or develop genetics-based healthcare therapies (D)

Furthermore, the Fund may not invest less than 51% of its Net Asset Value in Software used to facilitate online medical consultations (E) E-Commerce

equity securities which constitute "equity participation" within the meaning of pharmacies (F) Software for the management of medical practices and/or patient

section 2, Article 8 of the German Investment Tax Act. records (G) Outpatient medical Internet of Things devices which allow remote The Fund, using a “passive” or indexing investment approach, attempts to monitoring of health indicators such as heart rate and rhythm, or glucose levels,approximate the investment performance of the Index by investing in a portfolio of and be listed or traded on the Markets referred to in Appendix II of the securities that generally replicates the Index. The Investment Manager will Prospectus.

regularly monitor the Fund’s tracking accuracy. The Manager has categorised the Product as meeting the provisions set out in Recommendation: This Fund may not be appropriate for investors who plan to Article 9(1) of Regulation (EU) 2019/2088 on sustainability related disclosures in

withdraw their money within 5 years. the financial services sector ("SFDR") for products, which have sustainable

• Fund’s base currency: U.S. Dollar investment as their objective and where an index has been designated as a• Distribution policy: Income accumulated reference benchmark. The Index considers ESG factors as further detailed in the

The shares are admitted for trading on various stock exchanges and can be Index methodology available on the Index Provider’s website and in the

traded on the secondary market. The price of the shares offered on the Prospectus.

secondary market may deviate from the net asset value of the shares. The return Where it is not practical or cost efficient for the Fund to fully replicate the Index,

of the Fund is directly related to the return of the underlying assets minus the the Manager may utilise an optimised sampling methodology.

costs associated with the Fund. If the performance of the underlying assets The Fund may also (or alternatively) invest in financial derivative instruments

decreases, the performance of the Fund will also decrease. There is no capital (FDIs) which relate to the Index or constituents of the Index. The FDIs which theprotection against Market Risk. Fund may use are futures, options (puts and calls), swaps (including equity

Risk and Reward Profile Lower riskHigher risk

Liquidity Risks: Exists when a particular financial instrument is difficult to Typically lower reward Typically higher reward

purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.

1

23

4

56

7 Equity Market Risk: The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including The risk and reward indicator is calculated using historical and simulated

general economic conditions and sudden and unpredictable drops in historical data. Historical data may not be a reliable indication for the future.

value. An investment in the Fund may lose money. Therefore, the risk classification may change over time. Industry or Sector Concentration Risk: The Fund’s assets may be Even if the Fund is in the lowest risk category, it does not mean it is risk free orconcentrated in one or more particular sectors or industries. The Fund that capital is guaranteed or protected.may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively This Fund is ranked at 7 because funds of this type have experienced very high impact the Fund's performance to a greater extent than if the Fund’s rises and falls in value in the past. assets were invested in a wider variety of sectors or industries. The following risks can be materially relevant but are not necessarily adequately captured by the synthetic risk indicator and may cause additional loss:

For more information on risks, please see the “Risk Factors” section of the

Fund’s prospectus, available on www.vaneck.com. Charges The charges you pay are used to pay the costs of running the Fund, including*Not applicable to investors on the secondary market. Investors who buy or sell the costs of marketing and distributing it. These charges reduce the potential

shares via a market pay the costs charged by their financial intermediaries. growth of your investment.

Information on these charges can be obtained from the markets where the shares are listed and traded or from the financial intermediaries. One-off charges taken before or after you invest Entry charge None*

You can find more information on the charges in the cost section of the Fund’s prospectus and/or supplement. This is available at www.vaneck.com. Exit charge

None* The ongoing charges figure is based on expenses for the 12-month period ending These are the maximum charges that could be taken from your money before it 31 December 2024. This figure may vary from year to year. It excludes portfolio is invested or before we pay out the sale proceeds of your investment.

transaction costs.

Charges taken from the Fund over a year Ongoing charges

0.35%

Charges taken from the Fund under certain specific conditions Performance fee

None

Past Performance 0 %-5 ​-4.6%-4.6%

​-4.8%-4.8%

-4.8%

​-4.8%

​-5.1%-5.1%

-10

20202021

2022

20232024Fund

Index

Any indication of past performance is not a reliable indicator of future performance.

The chart shows the Fund’s annual performance in USD for each full calendar year over the period displayed in the chart. It is expressed as a percentage change of the Fund’s net asset value at each year-end. The Fund was launched on 02 September 2022.

Performance is shown after deduction of ongoing charges.

Practical Information The Depositary of the Fund is State Street Custodial Services (Ireland) Limited.remuneration committee, where applicable, may be obtained from the website Further information about the Company and the Fund including the prospectus www.vaneck.com and a paper copy is available, free of charge and upon request, and most recent annual reports and semi-annual reports is available free of at the registered office of the management company. The Company is subject to charge online at www.vaneck.com or on request at the registered office of the

the tax laws and regulations of Ireland. Depending on your own country of company. These documents are available in English and certain other languages.

residence, this may have an impact on your investment. Please consult your The Fund is a sub-fund of the Company, an umbrella fund structure comprisinginvestment or tax adviser for advice on your own tax liabilities. different sub-funds. This document is specific to the Fund stated at the beginning

Further details regarding the Index are available on the Index Provider's website: of this document. However, the prospectus, annual and semi-annual reports are

www.marketvector.com prepared for the Company rather than separately for the Fund.

VanEck Asset Management B.V. may be held liable solely on the basis of any The net asset value and other information is available online at www.vaneck.com.statement contained in this document that is misleading, inaccurate or Investors can buy or sell shares daily on stock exchange(s) on which the shares inconsistent with the relevant parts of the prospectus of the Fund. are traded. The Fund shares are traded on one or more stock exchanges.

Under Irish law, the Company has segregated liability between its sub-funds. The The details of the remuneration policy of the management company, VanEckFund’s assets will not be used to discharge the liabilities of other sub-funds of Asset Management B.V., including, but not limited to, a description of how

the Company. In addition, the Fund’s assets and liabilities are segregated and remuneration benefits are calculated, the identities of persons responsible for held separately from the assets of other sub-funds. awarding the remuneration and benefits including the composition of the

The Fund is authorized in Ireland and regulated by the Central Bank of Ireland (CBI). VanEck Asset Management B.V. is authorized in the Netherlands and regulated by the Dutch Authority for the Financial Markets (AFM). The key investor information is accurate as at 06 February 2025.